Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159964 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01159964 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 60 participants.
The verdict
NCT01159964, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
Interventions
- BIOLOGICAL Immunotherapeutic GSK2302032A, different formulations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-07-20 |
| Est. Completion | 2014-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159964
The ClinicalTrials.gov registry entry for NCT01159964 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunotherapeutic GSK2302032A, different formulations is the first listed.
NCT01159964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159964 about?
NCT01159964 is a clinical study titled "Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery". The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
What is the current status of trial NCT01159964?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-07-20. Estimated completion is 2014-09-10.
What interventions are being tested in trial NCT01159964?
The interventions under investigation include: Immunotherapeutic GSK2302032A, different formulations (BIOLOGICAL).
Who is sponsoring clinical trial NCT01159964?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.